Cheryl J. Fitzer‐Attas
Cheryl J. Fitzer‐Attas publishes mostly in Neurology, Molecular Biology and Cellular and Molecular Neuroscience, on topics such as Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments and Genetic Neurodegenerative Diseases.
- World rank
- #560,614 of 7,710,434 ranked researchers
- Rank in United States
- #193,427 of 1,627,098
- Works
- 49
- Citations
- 3.2k
- Citations per work
- 64.8
What does Cheryl J. Fitzer‐Attas research?
Cheryl J. Fitzer‐Attas's work is mostly in Medicine (39%), Biochemistry, Genetics and Molecular Biology (10%), Neuroscience (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1938.8%
- Medicine1938.8%
- Everything else1938.6%
- Life Sciences1122.6%
- 1Neurology25% of their works
- 2Molecular Biology10% of their works
- 3Cellular and Molecular Neuroscience8% of their works
- 4Radiology, Nuclear Medicine and Imaging7% of their works
- 5Oncology7% of their works
- 6Immunology5% of their works
Research topics
- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Monoclonal and Polyclonal Antibodies Research
- Parkinson's Disease and Spinal Disorders
- CAR-T cell therapy research
- Phosphodiesterase function and regulation
- Nuclear Receptors and Signaling
Which keywords describe Cheryl J. Fitzer‐Attas's research?
The keywords of their largest research topics: Parkinson's Disease, Mitochondrial Dysfunction, Dopaminergic Neurons, Neurodegeneration, Deep Brain Stimulation, Neurological Disorders, a-Synuclein and Genetic Risk Factors.
- cAMP Signaling
- NR4A2
- Chimeric Antigen Receptor
- Dropped Head Syndrome
- Therapeutic Antibodies
- Huntington's Disease
- Subthalamic Nucleus
- a-Synuclein
- Neurological Disorders
- Neurodegeneration
- Mitochondrial Dysfunction
- Parkinson's Disease
- Dopaminergic Neurons
- Deep Brain Stimulation
- Genetic Risk Factors
- Basal Ganglia
- Fc Receptors
- Protein Aggregation
- Camptocormia
- CAR T Cells
- Cyclic Nucleotide Phosphodiesterases
- Nurr1
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Parkinson's Disease334 topics
- Mitochondrial Dysfunction212 topics
- Dopaminergic Neurons172 topics
- Neurodegeneration172 topics
- Deep Brain Stimulation162 topics
- Neurological Disorders162 topics
- Genetic Risk Factors141 topic
- a-Synuclein141 topic
- Basal Ganglia111 topic
- Subthalamic Nucleus111 topic
- Fc Receptors71 topic
- Huntington's Disease71 topic
- Protein Aggregation71 topic
- Therapeutic Antibodies71 topic
- Camptocormia51 topic
- Dropped Head Syndrome51 topic
- CAR T Cells41 topic
- Chimeric Antigen Receptor41 topic
- Cyclic Nucleotide Phosphodiesterases31 topic
- NR4A231 topic
- Nurr131 topic
- cAMP Signaling31 topic
Where does Cheryl J. Fitzer‐Attas work?
Cheryl J. Fitzer‐Attas's main affiliation in the publication record is CHDI Foundation, United States.
How many publications and citations does Cheryl J. Fitzer‐Attas have?
OpenAlex counts 49 works and 3,173 citations for Cheryl J. Fitzer‐Attas, an h-index of 25, ranking #560,614 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Cheryl J. Fitzer‐Attas. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.